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Approximately 20% of all ischemic strokes and transient
ischemic attacks (TIAs) are due to atherosclerotic stenosis
of the internal carotid artery (ICA) segment that is close to
the carotid bifurcation. For the prevention of such strokes,
carotid artery stenting (CAS) is emerging worldwide as a
less invasive alternative to carotid endarterectomy (CEA).
Since the inception of the procedure a large number of
patients have received CAS. Various specialists including
neurologists, cardiologists, neurosurgeons, vascular
surgeons, and radiologists are performing carotid artery
stenting. A large number of registries are in place
reporting findings on CAS. Several randomized trials have
attempted to compare the efficacy and safety of CAS
versus endarterectomy. Some of these were terminated
prematurely while others are still in progress.
HISTORY OF CAROTID ENDARTERECTOMY
In 1953 DeBakey performed the first successful carotid
endarterectomy for the treatment of occluded cervical
carotid artery, which was followed by Eastcott who
performed the first carotid endarterectomy we know of in
which the circulation of the brain was intentionally
interrupted to remove a stenotic plaque.1 From these
initial experiences CEA evolved over the years and has
come to be accepted as the standard treatment for
carotid revascularization.
The North American Carotid Endarterctomy Trial (NASCET)
was the first well designed multicenter randomized trial
that demonstrated unequivocal benefit of surgery over
best medical management in symptomatic patients with a
severe carotid stenosis of 70% or greater.2 Patients with
symptomatic moderate carotid stenosis of 50-69% yielded
only moderate but definitive reduction in the risk of stroke,
while patients with stenosis of less than 50% did not
benefit from surgery.2,3 The benefit of CEA in patients with
e 70% was sustained at eight years of follow-up.3 There is
thus Level I evidence from randomized studies that in
properly selected patients CEA can reduce the relative risk
of stroke by approximately 50% in both symptomatic and
asymptomatic patients when compared with best medical
management.4,5
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ABSTRACT
In the past few years, the use of carotid artery stenting (CAS) for the treatment of extracranial carotid occlusive disease has
increased exponentially. It is perceived to be a safer and effective alternative to carotid endarterectomy (CEA). There is an
extensive wealth of data on carotid endarterectomy, which is one of the most thoroughly studied and extensively performed
vascular surgical procedures. Data available on CAS is still limited. Ongoing randomized trials comparing the two procedures
are facing difficulties in patient recruitment because of large numbers of registries and extensive use of CAS. Proponents of
CAS believe that stenting will become the default first-line therapy for patients with extra-cranial carotid occlusive disease.
Opponents of CAS point to the lack of evidence from randomized, controlled studies, and favor CEA over carotid artery
stenting by citing the extensive experience and well-established role of CEA. With many stakeholders involved in the care of
patients with carotid artery disease and the rapidly growing popularity of the procedure, there is concern that trials
attempting to answer this question may remain incomplete. This review discusses the history and evolution of carotid artery
stenting, the method, the variety of stents used, the use of antiplatelet agents, and the available data on safety and
efficacy. 
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BEGINNING OF CAROTID ARTERY STENTING
In 1980 percutaneous transluminal balloon angioplasty for
carotid artery stenosis was first reported.1 Subsequently in
1987 findings on internal carotid angioplasty in 48
patients with de novo atherosclerosis or post-surgical
restenosis were published.1 Gil-Peralta et al6 performed
85 balloon angioplasties in 82 patients with symptomatic
carotid stenosis of greater than 70% during a 4-year
period and reported a technical success rate of 92%
(residual stenosis <50%) with a 30-day mortality of 0%
and major morbidity rate of 4.9% which compared
favorably to the rates in ECST7 and NASCET.2
Despite showing favorable results, simple balloon
angioplast ies were associated with a number of
complications such as vessel wall recoil, angiographically
evident intimal dissection, and plaque dislodgement with
particulate embolization. Promising results from trials of
stent-assisted balloon angioplasties as opposed to simple
bal loon angioplasties in coronary ar ter ies led to
experimentation and trials of carotid angioplasty along
with stenting. Further improvements resulted in the use of
distal embolic capture devices, with the hope of improved
outcomes.
PATIENT SELECTION
Treatment of carotid stenosis by endovascular techniques
has the distinct advantage of being less invasive, thus
avoiding a surgical incision. In the absence of long term
follow-up results and randomized trials it is difficult and
premature to define the indications of carotid angioplasty
and stenting over carotid endarterectomy. The Stenting
and Angioplasty with Protection in Patients at High Risk for
Endarterectomy (SAPPHIRE) trial has shown non-inferiority
of CAS when compared with CEA in high-risk symptomatic
pat ients on ly.8 The Carotid  Revascularizat ion
Endarterectomy versus Stent ing Tr ia l (CREST)  is
attempting to answer the same question in low risk
patients.9 Several other trials are underway to answer this
question.  
In general, indications for carotid revascularization relating
to symptomatic status and lesion severity are similar for
endovascular and surgical strategies. A summary of
proven and acceptable indications as given by Roubin et
al10 is presented in Table 1.
Primary candidates for carotid artery stenting are patients
with serious comorbid medical or anatomical conditions
that increase the risk of open surgical procedures or
general anesthesia. Results from SAPPHIRE and various
prospective registries of carotid stenting in patients at high
risk support these indicat ions for CEA. Conditions
characterized as high surgical risk include advanced age,
significant cardiac and pulmonary disease, prior neck
irrad iat ion or rad ical surgery , restenosis a fter
endarterectomy, contralateral carotid occlusion, high
lesion behind the mandible, and low lesions that would
require thoracic exposure.1 0 CARESS was a Phase-I trial
that compared CAS with embolic protection and CEA in a
broad risk population and found equivalent 30-day stroke
or death risk in the two groups.11 The 30-day stroke and
death rates associated with CAS and CEA were not
signif icantly different in a recently published meta-
analysis. Lower rates of myocardial infarction and cranial
nerve injury were observed with CAS compared with
CEA.12 Major trials such as CREST and SPACE comparing
carotid artery stenting and CEA in low surgical risk patients
are still in progress.13,14 Once these trials are complete,
patient selection for CAS will become easier. However,
recruitment in these trials is slow and the data may not be
available for an additional 2 to 3 years.15 Roubin et al10
have suggested a decision-making algorithm (Figure 1).
METHOD
A complete neurologic history and examination is a pre-
requisite to any carotid stent procedure. A baseline brain
CT or MRI scan should be obtained to document pre-
existing in fraction(s) and to exclude non-vascular
neurologic disease such as tumor that may mimic TIA.
Furthermore, baseline laboratory va lues inc luding
complete blood count, serum chemistries, blood urea
nitrogen and creatinine, PT, APTT, INR as well as pre-
procedural EKG and chest radiographs are obtained.
Patients fast from midnight before the procedure but are
permitted to take their regular medications with sips of
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Table 1: Indications for Carotid Artery Revascularization*
INDICATION SYMPYTOMATIC ASYMPTOMATIC
LEVEL STENOSIS STENOSIS
P R O V E N 70-99% stenosis >60% stenosis
Periprocedural risk <6% Periprocedural risk <3%
Life expectancy >5 
y e a r s
A C C E P T A B L E 50-69% stenosis >60% stenosis
Periprocedural P e r i p r o c e d u r a l
complication risk <3% complication risk <3%
Planned CABG
U N A C C E P T A B L E <29% stenosis <60% stenosis
o r o r
Periprocedural Periprocedural risk >5%
complication risk >6% No indication for CABG
*Adapted from Roubin GS et al.  Circulation 2006; 113:2021-2030
water. Oral antihypertensive medication is withheld on the
day of the procedure. Peri-procedural adequately dosed
antiplatelet therapy is the key. Patients must receive
either a combination of clopidogrel 75 mg and aspirin 325
mg for 5 days before stenting, or alternatively a loading
dose of clopidogrel (600 mg) and aspirin (650 mg) at
least 4 hours before the procedure. Either heparin (70
IU/kg initial bolus targeting an ACT [Activated Clotting
Time] of > 300 seconds) or bivalirudin is administered
immediately  wi th sheath insert ion.1 0 C o n t i n u o u s
monitoring of pulse oximetry, intra-arterial pressure and
hearth rhythm is essential, as is meticulous control of
hemodynamics. To suppress bradycardic responses to
balloon inflation and stent implantation, intravenous
atropine (0.5 to 1.0 mg) should be administered just
before balloon insufflation. Hypotension is especially
notable in elderly patients with calcified stenosis but is
benign and rarely requires measures such as volume
expansion or intravenous pressor support. If a pressor is
needed dopamine is the drug of choice. After relief of
stenosis, any increase in blood pressure should be treated
aggressively with intravenous anti-hypertensives such as
nicardipine, hydralazine, or labetolol to avoid reperfusion
injury. Before occlusive balloon deflation, and in cases
where distal protection with an occlusive aspiration system
is used, lowering of blood pressure before deflation
protects the potential consequences of hyperperfusion.
The extent of diagnostic angiography is determined by
anatomic information obtained from pre-procedural non-
invasive studies; at a minimum, this should include
accurate evaluation of les ion severity, length and
characteristics such as calcification versus ulceration.
Preliminary diagnostic angiography of both carotid arteries
in a minimum of two planes is preferred with cervical and
intracranial views.    
The procedure is usually performed under conscious
sedation with local anesthesia of the femoral artery
region. A sheath is inserted into the common femoral
artery with the sheath size dependent on the stent used
and sheath length. A variety of stent delivery catheters are
available. A distal protection device is now routinely used;
it is carefully advanced across the lesion and deployed
distally. Using a smaller diameter balloon, a pre-stent
angioplasty is then performed. This creates enough room
for the stent  to cross safe ly . Once the stent is
satisfactorily positioned, it is deployed by immobilizing the
delivery catheter and retracting the outer sleeve (for self-
expanding stents) or inflating the balloon (for balloon-
expandable stents). Post-stent angioplasty is usually
performed if residual stenosis after stent deployment is
still >30%. Antero-posterior and lateral cervical and
intracranial angiograms should be obtained after stent
placement in all cases to exclude any embolic branch
occlusion and to document new patterns of flow.
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Figure 1: Proposed new paradigm for decision making emphasizing risk
stratification pertaining to carotid stenting*
Figure 2: Basic principles and designs of distal/embolic protection devices
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TYPES OF STENT
Various types of stent have been used in different clinical
trials. These are broadly classified into self-expanding and
balloon-expandable stents. They are either tubular in
design or have a coiled sheet design.1 6 Examples of
balloon-expandable stents are Palmaz-Schatz stent and
Intrastent. Examples of self-expanding stents are Smart
stent, Precise stent and Wallstent. NexStent was the first
stent with a coiled sheet design.16 In the SAPPHIRE trial,
Smart or Precise stents were used which are nitinol
stents.8 The BEACH trial used Wallstent.17 With balloon-
expandable stents there is concern of restenosis due to
stent collapse from external compression.1 Most registries
are now using self-expanding nitinol stents and the
balloon expandable stent for carotid stenting is no longer
being used in most centers.18
DISTAL PROTECTION DEVICE
The greatest risk associated with CAS is periprocedural
st roke resulting from the release, migration and
embolization of debris during balloon angioplasty of the
stenotic lesion. Theron et al, who used occlusion balloon
to avoid distal migration of clots and plaque fragments,
made the first attempt at distal protection during carotid
artery angioplasty in 1990.1 9 A number of embolic
protection devices are currently utilized in carotid artery
stenting.18 There are three basic design principles of how
most distal protection devices work. They could be distally
occlusive, filter distally, or work through flow reversal
(Figure 2).
In the past 5 years data from several large trials, series
and registries of carotid artery stenting have reflected on
the experience of embolic protection devices (EPDs) in
CAS.  These findings have confirmed that embolic
complications decrease significantly when an EPD is
employed. CAS with cerebral protection has been shown
to be a safe, effective and durable treatment of carotid
artery stenosis, yet there is no available Level I evidence
to support the routine use of EPDs.  However, in the
absence of a reproducible estimation of the emboligenic
risk posed by each carotid artery lesion, expert consensus
supports the use of an EPD in all CAS procedures.19
ROLE OF ANTI-PLATELET AGENTS
The rationale for early anti-platelet therapy is to (i) prevent
rapid thrombus formation immediately after arterial injury
due to angioplasty and stenting; and (ii) prevention of
potential embolization of thrombus fragments to distal
s i t e s .2 0 Benefits of combined anti-platelet treatment in
coronary artery stenting have long been established.2 1
Significant reduction in post-procedural myocardial
infarction and stent thrombosis in coronary angioplasty
studies has made dual anti-platelet therapy the standard
of care.22 A meta-analysis of all trials that compared e 2
oral anti-thrombotic strategies in patients undergoing
coronary stent placement to determine which treatment
optimally prevents adverse cardiac events in the 30 days
following stent insertion showed that (a) cilostazol plus
aspirin and (b) clopidogrel plus aspirin were statistically
indistinguishable from ticlopidine plus aspirin in preventing
major adverse cardiac events in the 30 days following
cardiac stent placement.23
The first randomized controlled trial to assess the benefits
of combined anti-platelet therapy (using a regimen of
aspirin and clopidogrel) in carotid artery stenting was
terminated prematurely. In this study, patients were
already on aspirin 75 mg daily and were randomized to
receive either intravenous unfractionated heparin for 24
hours following the procedure, or clopidogrel. A loading
dose of clopidogrel 300 mg was given 6-12 hours before
the procedure and again as 75 mg 2 hours prior to the
procedure. It was then continued as 75 mg daily for 28
days following stent placement. There was significant
reduction in adverse neurological outcomes in the dual
anti-platelet group without an additional risk of bleeding.
Restenosis and bleeding complications were higher in the
heparin group but did not reach statistical significance.
The study was terminated prematurely due to increased
bleeding complications in the heparin group, but the
conclusion favored dual antiplatelet therapy.21
Another s ing le center s tudy compared the dual
antiplatelet treatment ticlopidine 250 mg twice a day plus
aspirin 325 mg with a combination of heparin 24-hour
infusion and aspirin in patients who underwent CAS. This
study also demonstrated that dual anti-platelet regimen
has a statistically significant impact on reducing adverse
neurological outcomes without an additional increase in
bleeding complications. This study did not show any
significant difference in either hemorrhagic complications
or the thrombosis/occlusion rate between the two groups.
This study was also terminated prematurely because of an
important difference between the two groups in primary
end-point favoring dual antiplatelet therapy.24
CAROTID ARTERY STENTING - IS IT SAFE?
Carotid artery stenting is increasingly used in place of
carotid endarterectomy even though few randomized trials
have directly compared these alternatives. The initial
series of CAS showed a high stroke rate compared with
previously reported series of CEA; however, these studies
predated the use of cerebral protection.4 The CAVATAS
trial was the first large trial in which the risk of stroke or
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death within 30 days of treatment was comparable in the
two groups of CAS and CEA.2 5 Results from CAVATAS lend
support to the concept that endovascular techniques are
better than surgery because they avoid risks related to the
incision in the neck and the use of general anesthesia. This
trial, however, also predated the use of distal protection
devices.  
The first randomized trial that compared CAS with distal
protection device to CEA was the SAPPHIRE trial. The main
finding of SAPPHIRE was that CAS with the use of an EPD
was not inferior to carotid endarterectomy in the prevention
of stroke, death or myocardial infarction among patients for
whom surgery posed an increased risk. In the secondary
analysis, the cumulative incidence of stroke, death and
myocardial infarction as well as the cumulative incidence of
cranial nerve palsy and revascularization and the length of
stay, were lower among patients who received stents than
among those who underwent surgery. The results are not
generalizable to patients at low surgical risk. SAPPHIRE was
terminated early because patient recruitment fell after non-
randomized stent registries were established. The trial was
designed to test non-inferiority of CAS versus CEA (and
hence show equivalency); its results, therefore, cannot be
extrapolated to assume superiority of CAS over CEA in high-
risk patients.8
The ARCHeR (ACCULINK for revascularization of carotids in
high-risk patients) trial was also conducted on high-risk
patients. At 1 year, the incidence of major stroke and
death was 2.5% in ARCHeR II (with EPD) and 3.87% in
ARCHeR I (without a protection device).2 6 , 2 7 Several other
trials have shown the rate of major cardiac events and rate
of complications to be similar to those in SAPPHIRE and
ARCHeR trials.2 7 The CREST trial, currently underway,
intends to answer the question of safety and efficacy of
CAS as compared to CEA in low risk asymptomatic patients
as well.9 , 1 3 Preliminary data from the lead-in phase of
CREST suggests that CAS carries a low risk of stroke in
young, low-risk patients - stroke risk for patients ages 60-
69 was 1.3%; for patients aged 70-79 it was 5.4%, and in
patients > 80 years old there was a combined stroke and
death rate of 12%.9 These data strongly confirm previous
reports suggesting that octogenarians have an excessive
risk of stroke or death after CAS and that these patients
should be strongly considered for CEA or medical therapy. 
Certain other potential risk factors may make CAS less
safe. These include decreased cerebral reserve, evidence
of excessive tortuosity defined as e 2 bend points that
exceed 90o within 5 cm of the lesion, including the take-
off of the internal carotid artery (ICA) from the common
carotid artery (CCA) and heavy calcification defined as
concentric calcification e 3 mm in width and deemed by at
least 2 orthogonal views to be circumferentially situated
around the lesion.1 0
CAROTID ARTERY STENTING - IS IT EFFECTIVE?
Technical success with CAS resulting in >50% reduction
in residual stenosis has been reported even in the very
early series of CAS.6 Whether this translates into long-
term benefit of having decreased ipsilateral stroke and
overall mortality is yet to be established. The 30-day and
1-year results of most CAS trials are encouraging in this
regard. However, until the long-term results of these trials
are available it will be premature to reach conclusions. 
There is some data to support cognitive benefits of CEA. A
recent study showed similar cognitive benefits with
improvement in cogniti ve and memory funct ions
immediately after CAS.28 In this study, patients also had
MRIs with diffusion-weighted imaging (DWI) before and
after the procedure. DWI lesions were seen in 40% of
treated patients.  The cognitive benefits were obvious
despite DWI lesions. Improved perfusion in previously
under-perfused areas was hypothesized to be the cause of
improved cognitive functions. Limitations of the study
included a small number of patients and limited follow-up.
REOCCLUSION AFTER CAROTID ARTERY STENTING
Stent endothelialization is a slow process and is known to
take between 28 and 96 days to complete. During this
time the exposed metallic stent continues to act as a
source of platelet activation.2 1 Acute and subacute in-
stent thrombosis  fo llowing CAS is a well -known
complication. Earlier studies have reported a frequency of
0.5 to 2%.29 A case of >90% restenosis within the stent
seven months after CAS is reported.30 Another recent
paper reported in-stent thrombosis after the acute phase
but within 3 months of CAS in 3 patients. Of note, in all
these patients antiplatelet therapy had been
d i s c o n t i n u e d .2 9 Overall - and unlike the coronary and
intracranial circulations - the rates of long-term flow-
limiting restenosis in larger vessels such as the carotid
artery are extremely low. 
CONCERNS ABOUT CAROTD ARTERY STENTING
Current concerns about CAS include the large number of
specialties that are eager to provide CAS as a clinical
service; however, there is lack of consensus about
minimal el igibi l i ty  crite ria for per formance of the
procedure. Given the wide ava ilab ilit y of catheter
techniques and expertise in using them in other medical
areas, especially cardiology, stenting will be offered to
neurologically unselected patients who may not need it.31
In testing the benefits and risks of new treatments in
different patient groups, registries are not acceptable
because of their risks of bias. Unfortunately, randomized
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trials of CAS versus CEA are having difficulty in recruiting
patients and most of the new data is coming from
registries.
CONCLUSION
The value of CEA has been established by a wealth of
evidence from well designed, prospective, randomized
trials. Carotid artery stenting is a very strong contender for
carot id revascular izat ion along s ide carot id
endarterectomy. However, large-scale, well-designed,
randomized trials comparing the two procedures are facing
great hardship in recruiting patients. If these trials prove
unequivocal efficacy and safety of carotid artery stenting,
then CAS is likely to become the default procedure for
treatment of eligible patients. Despite its promise,
available information on the safety and efficacy of CAS
cannot as yet be generalized.  
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